Educational content on VJHemOnc is intended for healthcare professionals only. By visiting this website and accessing this information you confirm that you are a healthcare professional.

Share this video  

LLMC 2020 | MM: Are anti-BCMA immunotherapies ready for the frontline?

Adriana Rossi • 21 Oct 2020
LLMC 2020
Multiple Myeloma

Adriana Rossi, MD, Weill Cornell Medical College, New York City, NY, discusses on B-cell maturation (BCMA) targeted therapies in the treatment of multiple myeloma (MM). Dr Rossi highlights the status and roles of chimeric antigen receptor (CAR) T-cell therapies, bispecific T-cell engagers (BiTEs) and antibody-drug conjugates (ADCs). This interview was recorded via an online conference call with The Video Journal of Hematological Oncology (VJHemOnc).

Disclosures

Consulting for Amgen, BMS, Janssen

Related Videos

0:59
Looking forward to COMy 2024: celebrating 10 years
Mohamad Mohty • 17 Apr 2024
0:57
Overcoming barriers to treating older patients with myeloma
Sergio Giralt • 16 Apr 2024
1:01
The potentially curative role of CAR-T therapy in myeloma
Sergio Giralt • 16 Apr 2024
1:45
Expanded approval of cilta-cel in myeloma: the value of bringing CAR-T cells into earlier lines
Monika Engelhardt • 16 Apr 2024
The content of VJHemOnc is intended for healthcare professionals